e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
New models for treating airway diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cellular mechanisms underlying CCSP SNP association with chronic airway diseases
Lucie Knabe (Montpellier, France), Lucie Knabe, Jennifer Bonini, Jessica Varilh, Petit Aurélie, Isabelle Vachier, Pascal Chanez, Magali Taulan, Arnaud Bourdin
Source:
International Congress 2015 – New models for treating airway diseases
Session:
New models for treating airway diseases
Session type:
Poster Discussion
Number:
3579
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Lucie Knabe (Montpellier, France), Lucie Knabe, Jennifer Bonini, Jessica Varilh, Petit Aurélie, Isabelle Vachier, Pascal Chanez, Magali Taulan, Arnaud Bourdin. Cellular mechanisms underlying CCSP SNP association with chronic airway diseases. Eur Respir J 2015; 46: Suppl. 59, 3579
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Expression of vascular remodeling markers in relation to bradykinin receptors in asthma and COPD
Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases
Year: 2013
Discovery of candidate proteins, PIGR and SELENBP1, as novel markers of airway diseases in COPD
Source: Annual Congress 2013 –COPD: new markers of diseases
Year: 2013
IL-17A is elevated in patients with COPD and contributes to airway remodeling by acting on fibroblasts
Source: International Congress 2016 – What's new in biomarker analysis?
Year: 2016
Regulation of GROα production in human bronchial epithelial cells
Source: International Congress 2016 – Laboratory tests and cell biology in allergy and immunology
Year: 2016
The role of circulating mitochondrial DNA in modulating airway inflammation of chronic obstructive pulmonary disease
Source: International Congress 2014 – Cell biology 2014
Year: 2014
Up-regulation of EGFR gene family in COPD patients: Correlation with airway obstruction
Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases
Year: 2013
A possible role of Krüppel-like factor 5 in small airway wall fibrosis in COPD
Source: International Congress 2015 – Airway remodelling: recent developments
Year: 2015
Myofibroblast expression in airways and alveoli is affected by smoking and COPD
Source: Annual Congress 2013 –COPD: new markers of diseases
Year: 2013
Involvement of ferroptosis in COPD pathogenesis
Source: International Congress 2016 – Emerging concepts in lung disease pathogenesis
Year: 2016
Alterations of the soluble proteome of airway epithelial cells in COPD
Source: Annual Congress 2013 –New strategies in epigenomic research to study lung diseases (DNA rearrangements, RNA, methylation, proteosome)
Year: 2013
Modulation of inflammation by benralizumab in eosinophilic airway disease
Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma
Year: 2016
Current perspectives in epithelial cell injury and repair: consequences for epithelial functions
Source: Eur Respir Rev 2005; 14: 126-130
Year: 2005
Autoreactivity and inflammatory phenotypes in patients with COPD and bronchial asthma
Source: International Congress 2016 – Laboratory tests and cell biology in allergy and immunology
Year: 2016
TSPO a new anti-inflammatory target in the airway of COPD
Source: International Congress 2015 – Advances in the future treatment of COPD
Year: 2015
Pro-and anti-fibrotic molecule balance in the bronchial mucosa of stable COPD patients
Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases
Year: 2015
PCDH1: Localization and cell-adhesion in airway epithelium in asthma
Source: International Congress 2015 – Translational studies in airway cell biology
Year: 2015
Periostin: A key contributor to changes in the epithelial phenotype in asthma?
Source: International Congress 2015 – Clincal aspects of asthma: monitoring and mechanisms
Year: 2015
Altered airway epithelial cell specification in COPD
Source: International Congress 2015 – Translational studies in airway cell biology
Year: 2015
A role for WNT-5B in airway remodeling in COPD by activation of TGF-beta/Smad3 signaling?
Source: Annual Congress 2013 –COPD: experimental biology
Year: 2013
Inflammatory cell microlocalisation and airway dysfunction: cause and effect?
Source: Eur Respir J 2007; 30: 1043-1056
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept